Positive surgical margins, systemic disease, and prostate cancer-specific mortality

Researchers at the Mayo Clinic have queried their large, nearly 20-year-long database of men who have undergone radical prostatectomy in an attempt to assess the correlation between positive surgical margins at the time of surgery and subsequent occurence of systemic disease or prostate cancer-specific mortality. … READ MORE …

Pelvic lymph node dissection and prostate cancer-specific survival after surgery

According to an editorial commentary by Evans on the UroToday web site yesterday, a Canadian study published in BJU International last November has raised some interesting questions about the potential value of pelvic lymph node dissection (PLND) during the surgical treatment of men with prostate cancer of any stage. … READ MORE …

Does taking aspirin really reduce risk for prostate cancer-specific mortality?

A presentation to be given next week at the upcoming annual meeting of the American Society for Radiation Oncology (ASTRO) will suggest that men initially diagnosed with localized prostate cancer and who take an anti-clotting agent are at significantly lower risk for prostate cancer-specific death at 10 years of follow-up. … READ MORE …

A 45 percent reduction in prostate cancer-specific mortality? Not exactly.

According to a report yesterday in Consumer Affairs, “American men with prostate cancer were 45 percent less likely to die from the disease in 2006 than they were in 1999.” … READ MORE …

Comorbidities and risk for prostate cancer-specific mortality

It is not exactly news that men who are diagnosed with localized prostate cancer, but who have a significant number of comorbid conditions, are actually at relatively low risk of prostate cancer-specific mortality. … READ MORE …